Article citationsMore>>

Tanaka, H., Teramoto, S., Oashi, K., Saikai, T., Tanaka, S., Suzuki, K., et al. (2001) Effects of Candesartan on Cough and Bronchial Hyperresponsiveness in Mildly to Moderately Hypertensive Patients with Symptomatic Asthma. Circulation, 104, 281-285.
https://doi.org/10.1161/01.cir.104.3.281

has been cited by the following article:

• TITLE: Candesartan-Induced Cough Variant Asthma

  AUTHORS: Jessica Saliba, Amanda Darmanin, Sean Pace

  KEYWORDS: Candesartan, Cough Variant Asthma, Fractional Exhaled Nitric Oxide (FeNO)

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.14 No.8, August 22, 2025

  ABSTRACT: In this report, we present the case of a 56-year-old female who was seen at an outpatient clinic with a persistent cough shortly after starting Candesartan. This lady was not a known case of asthma and never presented with any asthma related symptoms. In fact, she led a very active lifestyle with no respiratory limitations which she couldn’t maintain after starting Candesartan. In the clinic, she was noted to have a high Fractional Exhaled Nitric Oxide (FeNO) (136 ppb) and Eosinophilia (0.44 × 109/L). Shortly after stopping Candesartan and starting Inhaled Corticosteroids (ICS), her symptoms resolved completely and she was able to return to her previous level of activity. She also managed to as needed ICS/Long Acting Beta Agonists (LABA) with no recurrence of symptoms on follow up review. To our knowledge, this is one of the few cases where Candesartan has contributed to cough in a predisposed asthma phenotype. It would be interesting to see if this case would highlight the association between Candesartan and cough variant asthma.